A phase II study of anlotinib in the first-line treatment of locally advanced or metastatic soft tissue sarcoma.

被引：0
|
作者：
Huang, Xin
Ye, Zhaoming
Li, Tao
Wei, Yongzhong
Wang, Shoufeng
Liu, Yunxia
Chen, Jia
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[2] Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China
[4] Nanjing Univ, Sch Med, Drum Tower Hosp, Nanjing, Peoples R China
[5] Hangzhou Third Hosp, Hangzhou, Peoples R China
[6] Nanjing Med Univ, Canc Hosp, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e23531
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23531
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial
    Karch, Annika
    Koch, Armin
    Gruenwald, Viktor
    TRIALS, 2016, 17
  • [22] A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial
    Annika Karch
    Armin Koch
    Viktor Grünwald
    Trials, 17
  • [23] A prospective, single-arm phase II study of pegylated-liposome doxorubincin combined with ifosfamide as first-line treatment for patients with advanced or metastatic soft tissue sarcoma
    Liu, X.
    Zhang, X.
    Cao, J.
    Wang, H.
    Wu, X.
    Luo, Z.
    ANNALS OF ONCOLOGY, 2020, 31 : S986 - S986
  • [24] Phase II trial of first-line high-dose ifosfamide in advanced adult soft tissue sarcoma
    Trarbach, T
    Scheulen, ME
    Schroder, J
    Stuschke, M
    Seeber, S
    Schutte, J
    TUMORDIAGNOSTIK & THERAPIE, 1997, 18 (02) : 57 - 60
  • [25] Phase II Trial of Cetuximab in Patients With Metastatic or Locally Advanced Soft Tissue or Bone Sarcoma
    Ha, Huan T.
    Griffith, Kent A.
    Zalupski, Mark M.
    Schuetze, Scott M.
    Thomas, Dafydd G.
    Lucas, David R.
    Baker, Laurence H.
    Chugh, Rashmi
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (01): : 77 - 82
  • [26] A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma.
    Yang, Bo
    Xiong, Qi
    Song, Qi
    Long, Yaping
    Guo, Gang
    Li, Hongzhao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] A phase II study of gemcitabine docetaxel combination in metastatic/unresectable locally advanced relapsed synovial sarcoma.
    Tansir, Ghazal
    Rastogi, Sameer
    Kumar, Akash
    Shamim, Shamim Ahmed
    Panday, Rambha
    Barwad, Adarsh
    Dhamija, Ekta
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma
    Gordon, Erlinda Maria
    Chawla, Sant P.
    Tellez, Walter Andree
    Younesi, Elan
    Thomas, Sonu
    Chua-Alcala, Victoria S.
    Chomoyan, Hripsime
    Valencia, Chrysler
    Brigham, Don Arlen
    Moradkhani, Ania
    Quon, Doris
    Srikureja, Amornchit
    Wong, Steven G.
    Tseng, William
    Federman, Noah
    CANCERS, 2023, 15 (03)
  • [29] Systemic treatment of advanced soft tissue sarcoma. An update
    Eigendorff, E.
    TRAUMA UND BERUFSKRANKHEIT, 2018, 20 (01) : 55 - 61
  • [30] Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
    Liu, Jiayong
    Gao, Tian
    Tan, Zhichao
    Li, Shu
    Xu, Jie
    Bai, Chujie
    Xue, Ruifeng
    Xie, Lu
    Zhang, Lu
    Fan, Zhengfu
    Guo, Wei
    CLINICAL CANCER RESEARCH, 2022, 28 (16) : 3473 - 3479
12345